Jeonjinbio전진바이오팜

Jeonjinbio's trailing revenue is roughly flat with 2025 but it remains loss-making, with a sharp share price fall over the past year.

Jeonjinbio, a Korean KOSDAQ-listed maker of household, wildlife-deterrent and pet products, reported trailing twelve-month revenue of about ₩13.7T to H1 2026 and an operating loss of about ₩413B. The share price closed at ₩2,045 on 19 October 2026, down 25.6% over one year, with a market cap of about ₩18.5T and a 52-week range of ₩1,482 to ₩3,485.

What stands out

• Revenue fell 28.9% in 2025 to about ₩13.7T after strong growth in 2022 to 2024, and the 2024 net profit of ₩4.3T is not repeated in the recent figures.
• Operating margin was -3% on a trailing basis and net margin -2.2%, with losses in 2023, 2025 and the trailing period.
• Cash of about ₩6.3T is shown with no borrowings listed, and liabilities to equity is 8.7%, so the balance sheet looks lightly geared.
• The price-to-book ratio is about 1.1 and no dividend yield is paid, while earnings-based ratios are not meaningful because of losses.
• Filings in mid-2026 were mostly insider and 5%+ holding reports plus the June 2026 half-year report; no news headlines were in the data.

What to watch

• The next full-year and quarterly results, to see whether revenue stabilises and operating losses narrow.
• Foreign ownership fell from 1.2% to 0.9% over 60 days, and foreign investors were net sellers over the last 20 days, so further flows are worth monitoring.
• Further insider or major-holder filings, and any future news, since the data does not explain the drivers behind the recent holding reports.